Six Principles for Getting Pharmaceutical Development Right from the Start

June 10, 2018

Pharmaceutical or biotechnology companies looking to outsource their API production are planning for success by looking at the entire development cycle. The growing desire to select one API partner to work with throughout the drug development process, and to potentially also synthesize commercial quantities, put an increased importance on the selection process.

Spotlight

Nordic Drugs

Few, if any, other players in the pharmaceutical market have the same level of knowledge of the specific conditions that apply in the Nordic region. To build further value through our unique concept, we are in constant search for strong and sustainable partnerships with companies that have the intention of expanding business into the Nordic region.

OTHER WHITEPAPERS
news image

Access to medicinal products

whitePaper | January 3, 2022

There are many factors that can prevent a patient from being able to obtain the medicine they need, ranging from selective marketing decisions by companies to products being too expensive or pharmacy stock-outs

Read More
news image

WILL PHARMA COMMIT TO DELIVERING AFFORDABLE THERAPEUTICS AGAINST COVID-19?

whitePaper | April 8, 2020

EPHA is a change agent – Europe’s leading NGO alliance advocating for better health. We are a dynamic member-led organisation, made up of public health civil society, patient groups, health professionals, and disease groups working together to improve health and strengthen the voice of public health in Europe.

Read More
news image

The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain

whitePaper | April 16, 2020

Over the past two years, the pharmacy industry has seen unprecedented increases in the prices of generic drugs, causing unexpected cost increases for payers and consumers, and spurring an investigation by the United States Congress. High generic drug prices have had an adverse effect on almost everyone in the pharmaceutical supply chain. Consumers face higher co-pays and prices and health plans are dealing with higher drug spend. Physicians are finding the need to prescribe alternative drug therapies while dealing with angry patients.

Read More
news image

Research and Development in the Pharmaceutical Industry

whitePaper | April 1, 2021

Every year, the U.S. pharmaceutical industry develops a variety of new drugs that provide valuable medical benefits. Many of those drugs are expensive and contribute to rising health care costs for the private sector and the federal government. Policymakers have considered policies that would lower drug prices and reduce federal drug expenditures. Such policies would probably reduce the industry’s incentive to develop new drugs.

Read More
news image

Manual No More: Automating the Scientific Data Lifecycle

whitePaper | May 23, 2022

The world’s scientific data today is a morass. 50-80% of research scientist and data scientist time is spent wrestling with data before they can focus on highervalue AI/ML and advanced analysis to help bring new life-saving therapeutics to market.

Read More
news image

Essential for Stable U.S. Supply Chains of Quality Pharmaceuticals

whitePaper | May 11, 2022

CDER is taking another step towards realizing the vision for pharmaceutical quality in the 21st century: a maximally efficient, agile, flexible manufacturing sector that reliably produces high-quality drug products without extensive regulatory oversight.

Read More

Spotlight

Nordic Drugs

Few, if any, other players in the pharmaceutical market have the same level of knowledge of the specific conditions that apply in the Nordic region. To build further value through our unique concept, we are in constant search for strong and sustainable partnerships with companies that have the intention of expanding business into the Nordic region.

Events